
    
      A single arm, open label, prospective, phase IV trial to evaluate safety and efficacy of
      icotinib as first-line treatment for the elder patients with advanced or metastatic (IIIb and
      IV) NSCLC and mutated EGFR.

        -  Primary endpoint to assess progression-free survival

        -  Secondary endpoints to assess the overall survival, objective response rate, disease
           control rate and so on.
    
  